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Abstract  
AIM: The present study considers of the prevalence of heart failure (HF) in patients suffering from 
acute myocardial infarction (AMI) in the University Hospital Centre of Tirana (UHCT) “Mother 
Theresa”; the demographic and clinical characteristics of the sample during hospitalization; and the 
main predictors of heart failure occurrence inside the group of patients suffering an AMI.  
MATERIAL AND METHODS: During a period of study from 2013-2015 we studied demographic 
and clinical data from 587 consecutive patients presenting with AMI; Framingham criteria were 
adopted for classifying patients with HF upon admission.  
RESULTS: A Killip class ≥ 2 was the main diagnostic criterion of HF during hospitalisation. HF was 
identified in 156 patients (26.6%). The subgroup with HF had significant differences when 
compared with the other patients with regard to age, sex (male), heart rate upon admission, systolic 
blood pressure on admission, previous episodes of AMI, glycemia on admission, previous 
antihypertensive treatment, previous revascularization procedures, peripheral vascular disease, 
chronic renal disease, ejection fraction (EF), anemia, and atrial fibrillation presence. Independent 
predictors for HF occurrence in the logistic regression model were EF, previous revascularization, 
peripheral vascular disease, age, sex, previous AMI, systolic blood pressure upon admission, and 
anaemia.  
CONCLUSION: As a conclusion, HF seems to be a common occurrence after AMI, in spite of 
changes in the epidemiological profile of the acute coronary syndrome. An increase in the incidence 
is registered as well, parallel to a decrease in the mortality following AMI. Attention must be shown 
for highly risked subpopulations, aged persons, patients with the previous coronary disease, and 
concomitant conditions. 
 
Introduction 
 
Heart failure (HF) represents a syndrome due 
to structural or functional heart disorders, hampering 
the ability of this organ to sufficiently pump the blood. 
HF will be accompanied with a shorter life expectancy, 
as well as other important symptoms such as 
dyspnea, fluid retention, fatigue and malaise, that will 
severely worsen the quality of life [1]. Coronary 
disease is recognised as the main cause of mortality, 
approximating 20% of all deaths due to cardiovascular 
conditions in Europe [2]. An improvement in the 
treatment of AMI, especially following reperfusion 
therapies, and the increased mean longevity have 
contributed to an increase of survivals following AMI; 
the same is valid for patients with HF generally [3-7]. 
Almost half of the newly diagnosed patients with HF 
ageing less than 75 years are due to coronary artery 
disease; and 60% of the patients with HF have a 
positive history for AMI [8, 9].  
HF is a common complication in patients 
suffering AMI, causing higher costs of treatment and a 
poor prognosis. Systolic dysfunction of the left 
ventricle is the main cause of HF following an AMI. 
The reasons for HF development in the majority of 
patients following an AMI include the myocardial 
necrosis and the structural remodelling of the ventricle 
that pursues. The process of remodelling produces a 
rapid appearance in the immediate period post-AMI, 
with the process slowing down thereafter. Studies 
suggest a bimodal form of HF appearance; the first 
peak coincides with the hospitalisation, and the 
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second peak the fourth day after admission [10]. 
 HF symptoms are variable, and hardly might 
one foresee those that lead toward a “chronic” HF. 
Different factors such as recurrent ischemia, the 
extent of myocardial necrosis, the so-called “stunned 
myocardium”, ventricle remodelling, mechanical 
complications and “hibernating myocardium”, will all 
play a role in the emergence of systolic ventricular 
dysfunction post AMI, be it in the setting of a HF or 
lacking the clinical picture of a HF. In a US study of 
2002, it resulted that 20% of AMI patients showed the 
clinical picture of HF, with 9% having a later 
appearance [11]. A French study suggested that 38% 
of AMI patients had the signs of HF within the first five 
days after the infarction [12]. Several sources suggest 
a higher HF risk in aged people, patients positive for 
cardiac diseases and diabetes mellitus [13]. 
Predictors of an early developing of HF include aged 
patients, diabetes, previous cardiac symptoms; 
whereas predictors of a later developing HF include 
hypertensive disease, male sex, tachycardia and 
higher values of cardiac enzymes. It seems that HF is 
more frequent in anterior AMI when compared to other 
regions of the heart. 
 There is not much information with regard to 
the profile of the coronary disease, risk factors, 
treatment methods and their influence on the 
prognosis of an AMI [14]. In Albania, a transitional 
south-eastern European country, only a few studies 
have approached the issue. A previously published 
paper aimed towards the evaluation of the incidence, 
and of the predictors of HF, in a sample population of 
AMI patients [15].  
The present study aimed to assess the 
incidence of HF developing in patients with AMI 
admitted and treated in the Coronary Intensive Care 
Unit of the “Mother Theresa” University Hospital 
Centre of Tirana, Albania. 
 
 
Materials and Methods 
  
We studied the demographics and clinical 
characteristics of the AMI patients during their 
admission, as well as the predictors of HF. The 
present is a prospective study, including the 
demographic and clinical data of 587 consecutive 
patients suffering from AMI, from January 2013 till 
May 2015. Framingham criteria were applied for 
diagnosing patients with HF upon admission, and a 
Killip class ≥ 2 was the diagnostic criterion of HF 
during the period of hospitalisation, I a three-week 
follow-up period. Valvular, non-ischemic cardiopathy 
was excluded from the study group.  
 The data collection included age, gender, 
educational status, body height and weight, blood 
pressure, type of myocardial infarction (with ST 
elevation or in absence of the latter; STEMI vs. 
NSTEMI [ST Segment Elevation Myocardial 
Infarction]), localisation, HF complications and the 
medical treatment applied. Glycemia and lipid profile 
were performed during fasting. A thorough patient 
history regarding other risk factors for coronary 
disease (smoking, hypertension, diabetes, and 
dyslipidemia) and previous positive history for AMI 
was collected as well. 
 The study protocol was approved by the 
National Committee of Medical Ethics (No. of the 
protocol 092). 
 The statistical analysis of discrete (qualitative) 
variables was performed through presenting the 
variables in percentage; continuous variables were 
presented as a mean value ± standard deviation. 
Groups were compared to each other with a 
2
 test for 
discrete variables, and t-test for continuous variables. 
A logistic regression model was used to determine 
independent predictors of the HF developing in AMI 
patients.  
 
 
Results 
  
HF was identified in 156 patients (26.6%) of 
the entire sample group of AMI patients. 
Epidemiological and clinical characteristics of the 
group are summarised in Table 1.  
Table 1: Clinical and epidemiological characteristics of the 
patients recruited in the present study 
Variable HF present HF absent P value 
Socio-demographic profile 
Number of patients 156 431  
Age, years  69.4 ± 11.2 61.7 ± 11.6 0.001 
Sex, male, n (%) 97 (62.3) 355 (82.4) < 0.0001 
BMI, kg/m2 26.4±3.7 26.7±2.8 0.381 
Clinical findings on admission    
Heart rate on admission, bpm  80.16 ± 19.35 70.64 ± 11.13 < 0.001 
Systolic BP on admission, mmHg 119.6 ± 30.5 132.9 ± 24.2 0.001 
Blood glucose on admission, mg/dl 168.5 ± 83.2 143 ± 77.4 0.007 
AMI location    
Anterior, n (%) 112 (71.8) 190 (44.1) <0.0001 
Inferior, n (%) 38 (24.4) 192 (44.5) <0.0001 
Presence of STEMI, n (%) 114 (73) 338 (78.4) 0.141 
LVEF (%) 36.9 ± 9.1 57.2 ± 5.7 <0 .0001 
Previous MI, n (%) 34 (21.8) 29 (6.7) <0 .0001 
Previous HTN treatment, n (%) 55 (35.3) 278 (64.5%) 0.0031 
Previous MI, n (%) 34 (21.8) 29 (6.7) <0 .0001 
Previous PCI or CABG, n (%)  16 (10.3) 15 (3.5%) 0.012 
Coronary risk factors    
Smoking, n (%) 74 (47.4) 196 (45.5%) 0.054 
Diabetes, n (%) 52 (33.4) 142 (32.9) 0.114 
Dyslipidemia, n (%) 75 (48.1) 207 (48) 0.987 
Hypertension, n (%) 125 (80.1) 343 (79.6) 0.923 
Co-morbidity    
Chronic renal disease, n (%) 19 (12.2) 17 (4) 0.005 
Anemia, n (%) 29 (18.6) 34 (7.9) 0.003 
Peripheral vascular disease, n (%) 18 (11.5) 15 (3.5) 0.005 
AF occurrence, n (%) 13 (8.4) 8 (1.8) 0.003 
In-hospital medication    
Beta blockers, n (%) 56 (35.9) 292 (67.7) <0.0001 
ACEI or ARB, n (%) 113 (72.4) 315 (73.1) 0.916 
Digoxin, n (%) 7 (4.5) 4 (0.9) 0.036 
Statins, n (%) 134 (85.9) 380 (88.2) 0.876 
Diuretics, n (%) 127 (81.4) 31 (7.2) <0.0001 
Plus – minus values are means ±SD. HF – heart failure; BMI – body mass index; BP – 
blood pressure; MI – myocardial infarction; HTN – systemic arterial hypertension; PCI – 
percutaneous coronary intervention; CABG – coronary artery bypass surgery; LVEF – left 
ventricular ejection fraction; AMI – acute myocardial infarction; STEMI – ST-segment 
elevation myocardial infarction; AF – atrial fibrillation; ACEI – angiotensin-converting 
enzyme inhibitor; ARB – angiotensin receptor blocker. 
 Myftiu et al. Heart Failure Predictors in a Patients with Myocardial Infarction 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2016 Sep 15; 4(3):435-438.                                                                                                                                                         437 
 
 The subgroup of patients with HF showed 
significant differences from other patients when 
compared with regard to age, gender (male), heart 
rate on admission, systolic BP on admission, previous 
MI, glycemia on admission, previous antihypertensive 
treatment, previous coronary revascularization 
procedures, peripheral vascular disease, chronic renal 
disease, ejection fraction, as well as anemia and for 
the presence of atrial fibrillation. No significant 
differences were met with regard to the presence of 
hypertension (p = 0.923), diabetes (p = 0.114), 
dyslipidemia (p = 0.987), presence of STEMI (p = 
0.141), smoking habits (p = 0.054).  
Table 2: Multivariate analysis of the predictors of heart failure, 
in a group of patients with acute myocardial infarction 
Variable OR (95% CI) P value 
Age [years] 1.83 (1.25 – 3.16) 0.002 
Sex [male] 0.42 (0.23 – 0.76) 0.047 
Glycemia on admission 1.72 (0.78 – 3.71) 0.211 
Systolic BP [mmHg] on admission 0.87 (0.63 – 0.91) 0.032 
Ejection Fraction 4.78 (1.73 – 13.03) 0.001 
Previous MI 1.89 (1.12 – 4.03) 0.013 
Chronic renal disease 1.79 (0.82 – 3.94) 0.0384 
Peripheral vascular disease 2.14 (1.57 – 4.36) 0.027 
Previous PCI or CABG 3.84 (1.34 – 11.62) 0.0016 
Anemia 1.69 (1.37 – 2.85) 0.046 
CI – confidence interval; BP – blood pressure; MI – myocardial infarction; OR – odds ratio; 
PCI – percutaneous coronary intervention; CABG – coronary artery bypass surgery. 
 
 Significant differences in between the two 
subgroups (with / without HF) were seen with regard 
to the usage of diuretics, digoxin and beta-blockers. 
Table 2 represents the multivariate analysis for the 
predictors of the acute HF in AIM patients. 
Independent predictors for the HF developing in a 
logistic regression model were: ejection fraction, 
previous revascularization, peripheral vascular 
disease, age, gender, previous myocardial infarction, 
systolic BP on admission, and anaemia. The data are 
graphically represented in Figure 1 as well, focusing 
on the statistical significance of every independent 
predictor separately.  
 
Figure 1: Multivariate analysis of predictors of heart failure in acute 
myocardial infarction patients 
 
 
Discussion 
 
 HF incidence in our study resulted in 26.6%, 
whereas other large clinical studies have suggested 
somehow higher values up to 29.4% (GUSTO I, 
GUSTO IIb, GUSTO III and ASENT II) [16]. Registry 
values, including the VALIANT register, suggest 
figures from 20.4% up to 24.5% [11, 17]. Another 
large epidemiological study including the period 1970-
1999, found that 24% of the AIM cases presented HF 
[18]. There are a few studies in Albania regarding the 
factors that might lead to HF developing in the acute 
phase of AMI [15, 19]. In our present paper, as well as 
in the Framingham analysis, HF patients were older, 
they showed a male preponderance, a higher heart 
rate on admission, higher systolic BP values on 
admission, positive history for previous MI as well as 
higher glycemic values on admission, together with 
more antihypertensive drug usage, an increased 
presence of previous attempts to coronary 
revascularization, peripheral vascular disease, chronic 
renal disease and anemia, a lower ejection fraction 
and an increased occurrence of atrial fibrillation. 
 With regard to risk factors, the HF subgroup 
of patients differed only for the smoking habits. As of 
the in-patient or intra-hospital treatment, our HF 
subgroup differed significantly with the subgroup 
without HF, vis-à-vis digoxin, diuretics and beta-
blockers administration. Predictors for an early 
development of HF were older patients, diabetics, and 
people suffering from previous cardiac symptoms; 
whereas predictors for a late-onset HF were 
hypertensive disease, male gender, tachycardia and 
higher value of cardiac enzymes. HF was more 
frequent following anterior AMI when compared with 
other anatomic cardiac areas.  
 In our study, independent predictors of the HF 
developing in a logistic regression model were: 
ejection fraction value, previous revascularization 
procedures, peripheral vascular disease, age, gender, 
previous MI, systolic BP on admission and anaemia. 
The simultaneous presence of different risk factors 
and the clinical severity of AMI, together with a 
suboptimal medical care, will strongly influence the 
prognosis of the coronary disease. In Albania, there is 
as well a need for rehabilitation programs, let alone 
the necessity of a standardisation of interventions 
aiming at secondary prevention. Obviously, other 
studies are needed to clarify the importance of factors 
influencing the clinical profile of Albanian patients 
suffering an AMI, in order to optimise the quality of 
care within a coronary intensive care unit. 
In conclusion, in spite of a falling trend of 
mortality linked to myocardial infarction, HF still 
remains an important complication of the everyday 
cardiologic practice. In order to better organise 
prevention and optimal treatment for the HF, an 
increased attention is needed towards highly risked 
populations, especially aged persons, those with the 
previous coronary disease, and other concomitant 
medical conditions. As a conclusion, we might say 
that HF is a common occurrence following AMI, 
notwithstanding changes in the epidemiology of the 
acute coronary syndrome. In fact, an increased 
incidence of HF is being reported, parallel to a 
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decrease in the mortality from AMI. Further 
observations are needed to demonstrate the impact of 
newly marketed drugs in the HF frequency after an 
AMI episode so that all requirements of an evidence-
based medicine might be accomplished.  
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